SEC Company Response from Moleculin Biotech, Inc. (MBRX) (CIK 0001659617) (MBRX) — Feb 8, 2017
Moleculin Biotech, Inc. (MBRX) (CIK 0001659617)
Date: Feb. 8, 2017 · CIK: 0001659617 · Accession: 0001144204-17-006736
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-214898
Letter
Re: MOLECULIN BIOTECH, INC.
February 8,
VIA FACSIMILE AND EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Registration Statement on Form S-1 (Registration No. 333-214898) -
Concurrence in Acceleration Request
Ladies and Gentlemen:
National Securities Corporation (“National”), as underwriter for the referenced offering, hereby concurs in the request by Moleculin Biotech, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:30 P.M. (Eastern Time) on February 8, 2017, or as soon as practicable thereafter, pursuant to Rule 461 under the Securities Act. National affirms that it is aware of its obligations under the Securities Act in connection with this offering.
Very truly yours,
NATIONAL SECURITIES CORPORATION
Show Raw Text
CORRESP
1
filename1.htm
February 8,
2017
VIA FACSIMILE AND EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Re: MOLECULIN BIOTECH, INC.
Registration
Statement on Form S-1 (Registration No. 333-214898) -
Concurrence in Acceleration Request
Ladies and Gentlemen:
National Securities
Corporation (“National”), as underwriter for the referenced offering, hereby concurs in the request by Moleculin
Biotech, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:30 P.M. (Eastern Time)
on February 8, 2017, or as soon as practicable thereafter, pursuant to Rule 461 under the Securities Act. National affirms that
it is aware of its obligations under the Securities Act in connection with this offering.
Very truly yours,
NATIONAL SECURITIES CORPORATION
By:
/s/ Jonathan Rich
Name: Jonathan Rich
Title: Executive Vice President